Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
303 Leser
Artikel bewerten:
(0)

Norgine Presents New Post-hoc Data Analyses Highlighting the Efficacy of PLENVU for Bowel Cleansing at DDW

LONDON, May 6, 2017 /PRNewswire/ --

Norgine B.V. today presented new post-hoc analyses from the phase III DAYB and MORA studies that demonstrate the high-quality cleansing efficacy of PLENVU®, a low volume, 1 litre PEG and ascorbate bowel preparation when compared to sodium picosulfate with magnesium citrate (CITRAFLEET®) and 2 litre PEG with ascorbate (MOVIPREP®) respectively when using site colonoscopist assessments.[1],[2] In addition, data from the DAYB study show that PLENVU® achieved statistically significant improvements in adequate cleansing rates using the Boston Bowel Preparation Score when compared to sodium picosulfate with magnesium citrate.[3]

(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

High cleansing efficacy:

  • In the DAYB study, when compared to sodium picosulfate with magnesium citrate (CITRAFLEET®) using a day before dosing, PLENVU® achieved significantly better cleansing success;
    • in the overall colon (73.3% vs 60.9%, P=0.003)[1]
    • and a high-quality cleansing of the ascending colon (36.3% vs 15.4%, P<0.001)[1]
  • In the MORA study, when compared to standard 2 litre PEG with ascorbate (MOVIPREP®), PLENVU® achieved a significantly improved rate of;
    • cleansing in the overall colon when administered as an evening/morning split-dose (97.0% vs 90.9%, P=0.003)[2]
    • high-quality cleansing in the ascending colon when administered as an overnight split-dose (74.8% vs 60.9%, P<0.001) or morning-only dose (75.8% vs 60.9%, P<0.001)[2]

Improved cleansing (Boston Bowel Preparation Scale) in evening only dosing when compared to sodium picosulfate with magnesium citrate;

  • PLENVU® achieved a statistically significantly increased proportion of adequate level cleansing of the overall (61.9% vs 47.3%, P=0.001) and ascending colon (66.9% vs 50.2%, P<0.001) in patients with Boston Bowel Preparation Scale scores[3]

PLENVU® has been shown to be well tolerated in studies versus standard 2 litre PEG with ascorbate, sodium picosulfate with magnesium citrate and trisulfate solution.[4],[5],[6]

Dr Alastair Benbow, Chief Development & Medical Officer, Norgine commented "These phase III data confirm the potential of PLENVU®, a low volume bowel preparation to replace standard bowel preparations. As colonoscopy is considered one of the most effective colorectal screening procedures, use of a highly efficacious bowel preparation such as PLENVU® is important to enable better detection of adenomas and polyps which ultimately will improve patients outcomes and save healthcare systems resources."

These data were presented at Digestive Diseases Week, 6-9 May 2017, Chicago.

The PLENVU® Phase III clinical trial programme includes three multicentre, randomised, parallel group studies: NOCT, MORA, and DAYB.

Colorectal cancer is the second most common cause of cancer-related mortality in Europe and the US, with 412,000 new diagnoses of colorectal cancer every year in Europe and 136,115 in the US.[7],[8]

PLENVU® data being presented at DDW on Saturday 6 May, 12:00 CDT

  • Bowel preparation quality of NER1006 versus standard 2L PEG with ascorbate as assessed by colonoscopists at site: a post-hoc analysis from a randomized controlled trial. Poster Sa1096
  • Bowel preparation quality of NER1006 versus sodium picosulfate + magnesium citrate as assessed by colonoscopists at site: a post-hoc analysis from a randomized controlled trial. Poster Sa1109
  • Achieving adequate level bowel preparation with evening only dosing of novel NER1006 versus sodium picosulfate + magnesium citrate: post-hoc analysis from a randomized controlled trial. Poster Sa1120
  • High cleansing efficacy of NER1006 also in the elderly; subgroup analysis of randomized phase 3 trials. Poster Sa1110

In August 2016, Norgine entered into a licensing agreement with Valeant Pharmaceuticals for PLENVU® in the US and Canada.

PLENVU®is not yet approved for use in the US or Europe. Norgine anticipates regulatory approval in Europe in 2017 and in 2018 in the US.

View the full release on http://www.norgine.com


1. Lewis S. et al. Bowel preparation quality of NER1006 versus sodium picosulfate + magnesium citrate as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial. Sa1109. Digestive Diseases Week, 6-9 May 2017

2. Manning, J. et al. Bowel preparation quality of NER1006 versus standard 2L PEG with ascorbate as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial. Sa1096. Digestive Diseases Week, 6-9 May 2017

3. Hassan, C. et al. Achieving adequate level bowel preparation with day before dosing regimens of NER1006 versus sodium picosulfate + magnesium citrate: post hoc analysis of a Phase 3 trial. Sa1120. Digestive Diseases Week, 6-9 May 2017

4. Bisschops R, et al. P0179 Efficacy and safety of the novel 1 L PEG and ascorbate bowel preparation NER1006 versus standard 2 L PEG with ascorbate in overnight or morning split-dosing administration: results from The phase 3 study MORA. UEG Journal 2016; 4(Suppl1): A218 - A219

5. DeMicco M, et al. OP375 Efficacy and safety of the novel 1L PEG and ascorbate bowel preparation NER1006 versus trisulfate solution in overnight split-dosing administration: results from the phase 3 study NOCT. UEG Journal 2016; 4(Suppl1): A415-A416

6. Schreiber, et al. P1266 Efficacy and safety of the novel 1 L PEG and ascorbate bowel preparation NER1006 versus sodium picosulfate + magnesium citrate in day before split dosing administration: results from the phase 3 Study DAYB. UEG Journal 2016; 4(Suppl1): A589-A590

7. Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915

8. Colorectal Cancer Statistics 2013. Centers for Disease and Control and Prevention. https://www.cdc.gov/cancer/colorectal/statistics/ [Accessed 25 April 2017]

Norgine Media Contacts
Isabelle Jouin, T: +44(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.